참고문헌 (51)

1. The Human Genome Project Factsheet. National Human Genome？Research Institute.[cited 2023 May 19] Available from: URL: https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genome-project. 

2. The Precision Medicine Initiative. [cited 2023 May 19] Available？from: URL: https://obamawhitehouse.archives.gov/precision-med？icine. 

3. Brainard J, Farver C. The diagnosis of non-small cell lung cancer？in the molecular era. Modern Pathology. 2019;32:S16-S26. 

   상세보기

4. Beatrice A, Valentina M, Federico B, Roberto DA, Massimo D,？Khawaja Husnain H. Precision Medicine in Lung Cancer:？Challenges and Opportunities in Diagnostic and Therapeutic？Purposes. In: Henry SP, editor. Lung Cancer. Rijeka: IntechOpen;？2020. p.7. 

5. Wang M, Herbst RS, Boshoff C. Toward personalized treatment？approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345-1356. 

   상세보기

6. Subbiah V, Wirth LJ, Kurzrock R, Pazdur R, Beaver JA, Singh H,？et al. Accelerated approvals hit the target in precision oncology. Nat Med. 2022;28:1976-1979. 

   상세보기

7. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung？cancer. Nat Rev Dis Primers. 2021;7:3. 

8. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I,？Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN？Estimates of Incidence and Mortality Worldwide for 36 Cancers？in 185 Countries. CA Cancer J Clin. 2021;71:209-249. 

9. Kang MJ, Jung KW, Bang SH, Choi SH, Park EH, Yun EH, et al.？Cancer Statistics in Korea: Incidence, Mortality, Survival, and？Prevalence in 2020. Cancer Res Treat. 2023;55:385-399. 

   상세보기

10. Chow, QML. Head and Neck Cancer. N Engl J Med. 2020;382:60-72. 

    상세보기

11. Miserocchi G, Spadazzi C, Calpona S, De Rosa F, Usai A, De？Vita A, et al. Precision Medicine in Head and Neck Cancers:？Genomic and Preclinical Approaches. J Pers Med. 2022;12:854. 

    상세보기

12. Chow, QML. Head and Neck Cancer. N Engl J Med. 2020;382:60-72. 

    상세보기

13. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI,？Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35. 

    상세보기

14. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE,？Grandis JR. Head and neck squamous cell carcinoma. Nat Rev？Dis Primers. 2020;6:92. 

15. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J.？Nasopharyngeal carcinoma. Lancet. 2019;394:64-80. 

16. Young A, Okuyemi OT. Malignant Salivary Gland Tumors.？[Updated 2023 Jan 12]. In: StatPearls [Internet]. Treasure？Island (FL): StatPearls Publishing; 2023 Jan-. Available from:？https://www.ncbi.nlm.nih.gov/books/NBK563022/ 

17. Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and？neck cancer: Recent advances and future directions. Oral Oncol.？2019;99:104460. 

18. Moskovitz J, Moy J, Ferris RL. Immunotherapy for Head and？Neck Squamous Cell Carcinoma. Curr Oncol Rep. 2018;20:22. 

    상세보기

19. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de？Castro G Jr, et al. Pembrolizumab alone or with chemotherapy？versus cetuximab with chemotherapy for recurrent or metastatic？squamous cell carcinoma of the head and neck (KEYNOTE-048):？A randomised, open-label, phase 3 study. Lancet. 2019;394:1915-1928. 

20. The Cancer Genome Atlas Network. Comprehensive genomic？characterization of head and neck squamous cell carcinomas.？Nature. 2015;517:576-582. 

21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA,？et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov.？2012;2:401-404. 

    상세보기

22. Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A,？et al. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck:？EORTC position and approach. Ann Oncol. 2018;29:2313-2327. 

    상세보기

23. Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK,？Gray D, et al. An interim report on the investigator-initiated？phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). J Immunother Cancer. 2019;7:72. 

    상세보기

24. Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et？al. Clinical and analytical validation of FoundationOne Liquid？CDx, a novel 324-Gene cfDNA-based comprehensive genomic？profiling assay for cancers of solid tumor origin. PLoS ONE.？2020;15:e0237802. 

    상세보기

25. Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman？SS, et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018;3:e122109. 

    상세보기

26. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced？melanoma: A first step toward manageable disease. Clin Cancer？Res. 2011;17:1658-1663. 

    상세보기

27. US FDA. Approval. [cited 2023 May 21] Available from: URL: https://www.fda.gov/drugs/resources-information-approved-dru？gs/fda-approves-dabrafenib-plus-trametinib-anaplastic-thyroid？-cancer-braf-v600e-mutation. 

28. Guthrie, G. Progress in treating rare cancers. [cited 2023 May 21]？Available from: URL: https://www.cancer.net/blog/2019-01/pro？gress-treating-rare-cancers-2019-advance-year. 

29. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval？Summary: Pembrolizumab for the Treatment of Microsatellite？Instability-High Solid Tumors. Clin Cancer Res. 2019;25:3753-3758. 

    상세보기

30. Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N,？Cassier PA, et al. Pembrolizumab in microsatellite instability？high or mismatch repair deficient cancers: updated analysis from？the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929-938. 

    상세보기

31. Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez？L, Gallagher PS, et al. FDA Approval Summary: Pembrolizumab？for the Treatment of Tumor Mutational Burden-High Solid？Tumors. Clin Cancer Res. 2021;27:4685-4689. 

    상세보기

32. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema？MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report？from the ESMO Precision Medicine Working Group. Ann Oncol.？2020;31:1491-1505. 

    상세보기

33. Amatu A, Sartore-Bianchi A, Siena S. NTRKgene fusions as novel targets of cancer therapy across multiple tumour types. ESMO？Open. 2016;1:e000023. 

34. Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro？M, et al. Targeting NTRK fusion in non-small cell lung cancer:？rationale and clinical evidence. Med Oncol. 2017;34:105. 

    상세보기

35. Marchio C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel？M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann？Oncol. 2019;30:1417-1427. 

    상세보기

36. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25-34. 

    상세보기

37. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al.？Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703-713. 

    상세보기

38. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRKAlterations in Pan-Cancer Adult？and Pediatric Malignancies: Implications for NTRK-Targeted？Therapeutics. JCO Precis Oncol. 2018;2018:PO.18.00183. 

39. Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with？non-small-cell lung cancer after a diagnosis of brain metastases.？Curr Oncol. 2013;20:e300-306. 

    상세보기

40. Roughley A, Damonte E, Taylor-Stokes G, Rider A, Munk VC.？Impact of Brain Metastases on Quality of Life and Estimated Life？Expectancy in Patients with Advanced Non-Small Cell Lung？Cancer. Value Health. 2014;17:A650. 

41. Remon J, Besse B. Brain Metastases in Oncogene-Addicted？Non-Small Cell Lung Cancer Patients: Incidence and Treatment.？Front Oncol. 2018;8:88. 

    상세보기

42. Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T,？et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak？interaction with P-glycoprotein. Neuro Oncol. 2020;22:819-829. 

43. US FDA. Approval. [cited 2023 May 21] Available from: URL: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tum？ors-ntrk-gene-fusions-0. 

44. US FDA. Approval. [cited 2023 May 21] Available from: URL: https://www.fda.gov/drugs/resources-information-approved-drugs/？fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. 

45. Krzakowski MJ, Lu S, Cousin S, Smit EF, Springfeld C, Goto K,？et al. Updated analysis of the efficacy and safety of entrectinib in？patients with NTRK fusion-positive solid tumors. Presented at？ASCO 2022 [Poster 91]. 

46. Bochtler T, Kramer A. Does Cancer of Unknown Primary (CUP)？Truly Exist as a Distinct Cancer Entity? Front Oncol. 2019;9:402. 

    상세보기

47. Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, et？al. Assessment of Clinical Benefit of Integrative Genomic Profiling？in Advanced Solid Tumors. JAMA Oncol. 2021;7:525-533. 

48. Adashek JJ, Kato S, Gumas S, Lee S, Okamura R, Sicklick J, et al.？86MO - Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved？outcomes. Presented at ESMO 2020. 

49. Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N.？Molecular characterisation and liquid biomarkers in Carcinoma？of Unknown Primary (CUP): taking the 'U' out of 'CUP'. Br J？Cancer. 2019;120:141-153. 

    상세보기

50. FDA Guidance for Industry. Master Protocols: Efficient Clinical？Trial Design Strategies to Expedite Development of Oncology？Drugs and Biologics. [cited 2023 May 21] Available from: URL:？https://www.fda.gov/media/120721/download. 

51. Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al.？Tipifarnib in Head and Neck Squamous Cell Carcinoma with？HRAS Mutations. J Clin Oncol. 2021;39:1856-1864. 

    상세보기